Synthesis and quantitative structure-activity relationships of diclofenac analogs
摘要:
The synthesis of a series of 2-anilinophenylacetic acids, close analogues of diclofenac, is described. These compounds were tested in two models used for evaluating the activity of nonsteroidal antiinflammatory drugs (NSAID's), inhibition of cyclooxygenase enzyme activity in vitro, and adjuvant-induced arthritis (AdA) in rats. Statistically significant correlations were found between the inhibitory activities of the compounds in these two models, indicating that cyclooxygenase inhibition seems to be the underlying mechanism for the antiinflammatory activity of these compounds. Quantitative structure-activity relationship (QSAR) analysis revealed that the crucial parameters for activity in both models were the lipophilicity and the angle of twist between the two phenyl rings. Optimal activities were associated with halogen or alkyl substituents in both ortho positions of the anilino ring. Compounds with OH groups in addition to two ortho substituents or compounds with only one or no ortho substituents were less active.
Fenamic acid hydroxamate derivatives having cyclooxygenase and
申请人:Warner-Lambert Company
公开号:US05155110A1
公开(公告)日:1992-10-13
The present invention is novel selected hydroxamic acid derivatives of fenamic acids having 5-lipoxygenase and cyclooxygenase inhibiting properties, pharmaceutical compositions for treating conditions advantageously affected by the inhibition and methods for treating these conditions in mammals, including humans suffering therefor.
Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
申请人:Exocell, Inc.
公开号:US06355680B1
公开(公告)日:2002-03-12
The present invention is directed to compositions that inhibit the nonenzymatic glycation of albumin,, as well as methods of using compounds that inhibit albumin glycation for the treatment of glycation-related pathologies.
Novel fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
申请人:WARNER-LAMBERT COMPANY
公开号:EP0316630A1
公开(公告)日:1989-05-24
The present invention is novel selected hydroxamic acid derivatives of fenamic acids having 5-lipoxygenase and cyclooxygenase inhibiting properties, pharmaceutical compositions for treating conditions advantageously affected by the inhibition and methods for treating these conditions in mammals, including humans suffering therefor.